neostigmine + glycopyrrolate

This is an investigational dual-drug combination of neostigmine and glycopyrrolate being developed by the US Department of Veterans Affairs for the treatment of neurogenic bowel dysfunction in patients with spinal cord injury. Neostigmine is a cholinesterase inhibitor that increases cholinergic tone by blocking acetylcholine metabolism, thereby stimulating colonic motility and promoting bowel evacuation. Glycopyrrolate is an anticholinergic agent co-administered to attenuate peripheral cholinergic side effects of neostigmine, such as bradycardia and bronchoconstriction, while preserving its beneficial effects on the colon. The combination has been evaluated in multiple delivery routes, including intravenous, intramuscular, and transdermal administration, with a recent Phase 2 study focusing on an intranasal spray formulation to provide a more practical administration route for patients with spinal cord injuries.

Other names

neostigmine and glycopyrrolateintranasal neostigmine and glycopyrrolate